In a 69-year-old male undergoing radiation therapy for lung cancer who is severely depressed, what medication should be initiated?

Initiate an SSRI (such as fluoxetine or paroxetine) or mirtazapine for this severely depressed lung cancer patient undergoing radiation therapy

For a 69-year-old male with severe depression during radiation therapy for lung cancer, initiate pharmacologic treatment with an SSRI (selective serotonin reuptake inhibitor) or mirtazapine, as these are the most commonly used and well-tolerated antidepressants in cancer populations, though evidence shows no single agent is definitively superior to another. 1

Rationale for Pharmacologic Intervention

The 2023 ASCO guideline on depression management in cancer survivors found that while psychological interventions (CBT, behavioral activation, collaborative care) have strong evidence, pharmacologic management is appropriate for severe depression 1. The guideline acknowledges that a 2018 Cochrane review showed no difference between antidepressants as a class versus placebo at 6-12 weeks, but this was based on low-quality, limited studies 1. In real-world clinical practice with severe depression, waiting for psychological interventions alone is not appropriate—pharmacotherapy should be initiated promptly.

Specific Medication Recommendations

First-Line Options:

• SSRIs (fluoxetine, paroxetine, sertraline): Most commonly prescribed class in oncology patients 2. Fluoxetine specifically improved quality of life, emotional function, and reduced pain, fatigue, and insomnia in cancer patients with depression 3

• Mirtazapine: Particularly useful in this population due to:

  • Appetite stimulation (addresses cancer-related anorexia)
  • Sleep improvement (addresses insomnia common in cancer)
  • Minimal drug interactions
  • Evidence in terminally ill cancer patients when combined with methylphenidate for rapid response 1
  • Favorable profile in end-of-life care when combined with paroxetine, showing complete resolution within 10 days 4

Emerging Evidence:

• Vortioxetine: A 2025 real-world study showed this multimodal antidepressant had the most favorable tolerability profile with no reported adverse effects and was the most frequently prescribed individual agent, particularly in chemotherapy patients 2. However, this is newer evidence and not yet incorporated into guidelines.

Key Clinical Considerations

Avoid the common pitfall of underdosing or waiting too long to treat. Depression in cancer patients is frequently underdiagnosed and inadequately treated 5. With severe depression, aggressive treatment is warranted even in advanced disease, as it can dramatically reduce patient and family distress and improve quality of life 4.

Selection Factors (per ASCO guidelines 1):

• Adverse effect profile: Consider nausea/GI effects (common with SSRIs), sedation (mirtazapine), sexual dysfunction (SSRIs)
• Drug interactions: Critical in cancer patients on multiple medications—SSRIs have more cytochrome P450 interactions than mirtazapine
• Concurrent symptoms: If insomnia and poor appetite predominate, favor mirtazapine; if fatigue is severe, consider adding methylphenidate 1
• Prior treatment response: If patient previously responded to a specific agent, use that

For Lung Cancer Specifically:

Lung cancer patients with advanced disease showed significant depression reduction with collaborative care approaches combining behavioral therapy 1, but this patient is severely depressed and needs immediate pharmacologic intervention alongside any psychological support.

Alternative Considerations

If rapid response is critical (patient is actively suicidal or profoundly impaired): Consider mirtazapine plus methylphenidate combination, which showed antidepressant response from day 3 onward in terminally ill cancer patients, though with increased risk of nervous system adverse events 1.

If inflammation is suspected as a major driver (high symptom burden, systemic inflammation): Celecoxib showed decreased depression scores at 4-6 weeks in small trials 1, though this is not standard practice and requires more evidence 6.

Monitoring and Adjustment

• Reassess at 2 weeks for tolerability and early response
• Full therapeutic trial requires 4-6 weeks
• If partial response, consider combination therapy with CBT or interpersonal psychotherapy 1
• If no response, switch to different class rather than continuing ineffective treatment

The choice between SSRI and mirtazapine should be based on the patient's specific symptom profile, concurrent medications, and tolerability concerns, but either represents an appropriate evidence-based first-line choice for severe depression in this clinical context.